Journal of Nuclear Cardiology

, Volume 20, Issue 2, pp 205–213

The safety and tolerability of regadenoson in patients with end-stage renal disease: The first prospective evaluation

  • Rami Doukky
  • Maria Octavia Rangel
  • Marwan Wassouf
  • Rizcallah Dick
  • Ammar Alqaid
  • Raysa Morales Demori
Original Article

DOI: 10.1007/s12350-012-9654-2

Cite this article as:
Doukky, R., Rangel, M.O., Wassouf, M. et al. J. Nucl. Cardiol. (2013) 20: 205. doi:10.1007/s12350-012-9654-2

Abstract

Background

There has not been any prospective evaluation of the safety and tolerability of regadenoson (REG)-stress in patients with end-stage renal disease (ESRD).

Methods

From the pooled database of two identically designed randomized, double-blinded, placebo-controlled clinical trials, ASSUAGE and ASSUAGE-CKD (IV-aminophylline vs placebo following REG-stress), we extracted the placebo-treated subjects to form 2 study groups: ESRD (dialysis or GFR < 15 mL/minute/1.73 m2) and control (GFR ≥ 30). The incidence of REG adverse effects and the hemodynamic and ECG responses to REG-stress were compared.

Results

We identified 146 ESRD subjects and 97 controls. There was no significant difference in the incidence of the composite of any REG adverse effect [ESRD 108 (74%) vs control 73 (75%), P = .82]. ESRD patients seem to have excess incidences of diarrhea [42 (29%) vs 14 (14%), P = .009] and fewer events of dizziness [28 (19%) vs 43 (44%), P < .001]. There were no serious adverse events in either group. There was no significant difference in the incidence of ST-segment deviation, tachyarrhythmias, atrioventricular block, or hypotension.

Conclusion

This is the first prospective study to confirm the safety and tolerability of REG in patients with ESRD.

Keywords

Regadenoson end-stage renal disease (ESRD) chronic kidney disease (CKD) safety tolerability 

Copyright information

© American Society of Nuclear Cardiology 2012

Authors and Affiliations

  • Rami Doukky
    • 1
  • Maria Octavia Rangel
    • 1
  • Marwan Wassouf
    • 1
  • Rizcallah Dick
    • 1
  • Ammar Alqaid
    • 1
  • Raysa Morales Demori
    • 1
  1. 1.Section of CardiologyRush University Medical CenterChicagoUSA

Personalised recommendations